Aug 25 (Reuters) - AirXpanders Inc AXP.AX :
* Xpand pivotal trial meets primary endpoint
* Says pivotal xpand trial has met its primary endpoint in patients who have
undergone a mastectomy
* Says results will be submitted to the U.S. FDA as part of the co's 510(k)
dossier which is planned to be delivered to the FDA shortly.
* Source text for Eikon ID:nPnc4Nx0z
* Further company coverage AXP.AX